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SUMMARY.-The rat Walker 256 tumour was grown in mice that had
previously been thymectomized and treated with anti-lymphocyte serum.
These rat tumour-bearing mice were used to determine the therapeutic indices
of 4 anti-tumour drugs.
The agent with the highest index of the four examined was 5-aziridino
2,4-dinitrobenzamide (CB1954), followed by melphalan, aniline mustard and
methotrexate,, in that order. This rank order is the same as that found when
therapeutic indices are determined on the Walker tumour growing in the rat.
In this system, therefore, drugs have been ranked correctly in effectiveness
against a rat tumour by measuring their effects on the tumour.when growi'ng
in an immunosuppressed xenogeneic species. The implications for testing
the drug sensitivity of individual human tumours before treating the patient
are discussed.
CONSIDERIED as a whole, the results ofchemotherapy of,human neoplasms are
disappointing. Except in acute leukaemia and conditions where host factors
may be ofunusual importance, such as choriocarcinoma and Burkitt's lymphoma,
the majority of patients with neoplastic conditions obtain little or no objective
benefit from chemotherapeuticregimens that are ofconsiderabletoxicity. Never-
theless, it is indisputable that a minority ofpatients with solid tumours, usually
between 5 and 25% in different series, do have excellent remissionslasting months
or years. Examples are given for C.N.S. tumours by Smart et al. (1968), for
ovarian and mammary tumours by Foley, Lemon and Afiller (1970) and for
carcinoma of the cervix by Papavasiliou, Angelakis, Gouvalis and Papakyriades
(1969). It is also commonly found that a tumour resistant to one drug may be
sensitive to another.
There is at present no reliable way ofdiscovering, before treating the patient,
which of the available drugs would be most effective against any particular
tumour. In consequence, the considerable improvement obtained in a minority
ofpatients is held by many to be more than counterbalanced by the toxicity and
hazard undergone by the majority who derive no material benefit from such
treatment.
Considerable effort has accordingly been devoted to finding a method for
determining the sensitivity to drugs of tumour removed from the patient, either
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There are disadvantages in using tumours in tissue culture for this purpose.
Their environment is very different from that in the patient and it is to be
expected that their response to drugs will be modified accordingly. Further,
culture for more than a few cell generations inevitably selects some cell clones
at the expense of others and the sensitivity of these to drugs may not reflect that
of the tumour in vivo.
For these reasons, tumours growing in xenogeneic hosts may be more likely
to yield results of clinical relevance. Pioneer work was carried out by Toolan
(1953, 1958) using irradiated or cortisone-treated rats, mice and hamsters.
Various lines of human tumour cells have been established that are indefinitely
transplantable in appropriately treated animals. The xenogeneic transplantation
of tumours newly obtained from the patient has been generally rather less
successful. Handler, Davies and Sommers (1956) found that only 10 out of 68
miscellaneous human tumours grewprogressively in the hamster cheek pouch and
none of these could be serially transplanted. Patterson, Patterson and Chute
(1957) also found that 90% of human tumours either did not survive trans-
plantation to the cortisone-treated hamster or grew only-scantily. Ten per cent
grew well and could be serially propagated. A possible drawback to using
cortisone-treated animals for testing the drug sensitivity of tumours is that it is
usually necessary to continue its administration after transplantation. Cortisone
may modify the metabolism of other anti-tumour agents (Hayakawa et al., 1969)
and it is itselftoxic to many tumours. It is therefore desirable to use agents that
either do not require to be administered after tumour transplantation, or that
do not affect the tumour or the metabolism ofanti-tumouragents. A considerable
advance was made possible when anti-lymphocyte serum (ALS) was shown to
prolong the survival of xenogeneic transplants (Lance and Medawar, 1968).
Phillips and Gazet (1967) found that transplantable human carcinoma cell
lines would grow for at least 13-15 days in ALS-treated mice. These tumours
regressed within a month but, if the mice had previously been thymectomized,
progressive growth for at least a month was obtained (Phillips and Gazet, 1968).
Subsequently, these workers attempted to transplant 66 human tumours to
ALS-treated mice. In 12 of these, tumour tissue that appeared viable on histo-
logical examination was found up to 25 days after transplantation (Phillips and
Gazet, 1970).
It therefore appears that some human tumours can be grow-n in mice for a
matter of weeks, using immunosuppressive manoeuvres that do not affect the
tumour directly. It remains to be established whether the drug sensitivity of
suchtransplanted tumours reflects their sensitivity in the patient. Burt, Pavone-
Macaluso, Horns and Kaufman (1966) found that a human bladder cancer, which
had been sensitive to 5-fluorouracil and X-rays and insensitive to vincaleuko-
blastine in the patient, retained this spectrum ofsensitivities aftertransplantation
to immunosuppressed hamsters. Subsequently Kaufman and Lichtenauer (1967,
1968) investigated the effects of several drugs on human bladder cancersgrowing
in the cheek pouch of hamsters immunosuppressed with cortisone and cyclo-
phospharnide. Consistentinhibitory effects were obtainedonly with 5-fluorouracil
and mitom cin C, and not with vincaleukoblastine, viiicristine, cyclophosphamide.
thiotepa, streptonigrin, methotrexate, sarcolysin or carzinophilin. Again, one
tumour known to be sensitive to 5-fluorouracil and X-rays in the patient was
sensitive also when growing in bamsters (possibly this was the same tumour as
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that described by Burt et al., 1966). These examples are encouraging but hardly
conclusive as they relate only to 1 or 2 tumours. Smith (1969a) transplanted
16 human tumours to the cheek pouch of apparently untreated hamsters and
found that they varied in sensitivity to methotrexate and nitrogen mustard.
Thisvariability wasthought tosuggest that human tumours retain their individual
drug sensitivities while growing in the hamster, but no information was provided
as to the drug sensitivities of the tumours in the patients. It is not surprising
that tumours growing in xenogeneic hosts can be damaged by cytotoxic agents
and that they vary in sensitivity, but this is far from showing that sensitivity in
the patient and in the transplantrecipient are correlated.
Before a large-scale investigation on human tumours can be justified, it
would be desirable to establish the validity of this system, using transplantable
rodent tumours of well-characterized drug sensitivity. Again, there is a certain
amount of evidence on this point in the literature. Forinstance, Handler (1958)
found that the mouse P1534 leukaemia, which was sensitive to actinomycin D
and resistant to aminopterin, retained this differential sensitivity while growing
in the hamster cheek pouch. Smith (1969b) showed that doses of nitrogen
mustard and methotrexate that caused incomplete regression of the Walker 256
rat tumour would also incompletely inhibit this tumour when it was grown in
the hamster cheek pouch, but his experiments did not attempt to rank the two
drugs in order of effectiveness.
It remains to be established, therefore, whether the drug sensitivity of a
rodent tumour when growing in an immunosuppressed xenogeneic species would
usefully reflect its sensitivity in the species oforigin. We decided to investigate
this, using the Walker 256 rat tumour, which iswidely used intesting anti-tumour
drugs (Schmidt, Fradkin, Sullivan and Flowers 1965; Rosenoer, Mitchley, Roe
and Connors, 1966), and grows well in ALS-treated mice (Kubista, Shorter and
Hallenbeck 1967).
MATERIALS AND METHODS
Immunosuppressionofmice.-Female BA-LB/c mice werethymectomized under
Avertin anaesthesia at 8-10 weeks of age. Antilymphocyte serum prepared
by the method of Levey and Medawar (1966), inactivated at 56' for 30 minutes
and stored at -70', was 4iven subcutaneously in 4 doses of 0-5 ml per mouse on
alternate days, starting 4-5 days afterthymectomy.
Tumour transplantation.-The Walker 256 tumour, received from the Chester
Beatty Research Institute, was maintained in ascitic form by weekly intra-
peritoneal passage of 2 x 105 cells in female Wistar rats weighing 150-200 g.
Transplantation into immunosuppressed mice was effected by a subcutaneous
injection of 2 x 105 cells into the flank one day after the last injection of ALS.
Drugs
Melphalan (p-di-"")-chloroethylamino-2-phenylalanine) was obtained from Bur-
roughs Wellcome Ltd. It was dissolved in buffer according to the manu-
facturer's instructions.
Aniline mustard (N N-di-(2-chloroethyl)-aniline) was obtained from the Chester
Beatty Research Institute. It was dissolved in dimethyl sulphoxide, the
required dose being given in a volume of 2 ml./kg.IM) F K, a-- - -x
L) . -Im lw.ff .
e%, 100
Syxnbols as in Fig. 1.
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Methotrexate, 8odium 8alt was obtained from Lederle Laboratories Ltd, and
dissolved in saline for injection in a volume of 10 ml./kg.
5-Aziridino 24-dinitrobenzamide (CB 1954) was obtained from the Chester Beatty
Research Institute and was dissolved in dimethyl sulphoxide for injection in
a volume of 2 ml./kg.
FIG. I.-Toxicity and anti-tumour effect of CB1954 Walker 256 tumour grown in mice.
x, per cent survival; 0, mean tumour weight as percentage of control. The vertical bars
show one standard error. Each point represents a group of 5 mice.
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FiG. 2.-Toxicity and anti-tumour effect ofmelphalan.
Experimentalprocedure
The various drugs, dissolved freshly on the day of administration, weregiven
intraperitoneally once on the day after tumour inoculation, with the exception
of methotrexate which was given daily for 5 days, starting on the day after
tumour inoculation. Control mice were inoculated with tumour cells and given
the drug solvent only. Groups of 5 mice were used for each dose ofdrug. Ten
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days after transplantation, all aiiimals were killed and their tumours removed
aDd weighed. Tumour weights were calculated as percentages of the control
weight, which were generally about 2 nu.
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Fic,,. 3.--Tox'cit effect of an'lii-ie mustar(l. I y- an(I aiiti-tumour Symbols as in Fig. 1.
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Fic- 4.-Toxicity and anti-turnour effect of methotrexate. Symbols as in Fig. 1.
The 10-day LD50 and ID90 (the dose that reduced tumour weight by 90%)
were determined by interpolation on semilogarithmic plots, and the therapeutic
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RESULTS
These are shown in Fig. 1-4. The rank order of effectiveness of the 4 com-
pounds is CB1954 > melphalan > aniline mustard > methotrexate, with thera-
peutic indices 130, 22-5, 12-0 and 1-65 respectively.
DISCUSSION
The experimental protocol of tumour transplantation, drug administration
and assessment of results was the same as that used in the routine testing of
drugs against the Walker tumour in the rat at the Chester Beatty Research
Institute. Table I compares the results obtained when the tumour grows in
the species of origin (T. A. Connors, personal communication) with those we
have obtained when the tumour grows in the immunosuppressed mouse.
TABLE I.-The, LD5 0) ID 90 and Therapeutic Indicesfor Drugs Te8ted
Against the Walker Tumour in the Ra-t and Mou8e
Drug CB 1954 Melphalan Aniline mustard Methotrexate
LD50
Rat 27 4
- 75 84 2
- 8
Mouse 220 18 100 1-9
ID90
Rat 0-4 0- 185 5-8 1-5
Mouse 1-7 0- 8 7
- 8 1.15
TI
Rat 67 25- 7 14-5 i-9
Mouse 130 22- 5 12-8 1-65
It is clear that, when this rat tumour is grown in thymectomized, ALS-treated
mice, the therapeutic indices of 4 anti-tumour agents have the same rank order
in both species. This is so even though the rank orders of toxicity and anti-
tumour activity are different (CB 1954 is more toxic than aniline mustard on a
mg./kg. basis in the rat but the reverse is true in the mouse; CB 1954 is more
tumour-inhibitory than methotrexate in the rat and the reverse is true in the
mouse). The probability of 4 agents being assigned the same rank order by
chance is 1/4! or 0.042 (i.e. P < 0.05).
It appears therefore that it is possible to rank drugs in order of effectiveness
against a tumour by testing their effects on the tumour when transplanted to an
immuiriosuppressed xenogeneic species. This method may be applicable to
sensitivity testing of drugs against individual human tumours, but there are a
number of reasons why this may be more difficult than in the experiments
described here.
First, the close correspondence in therapeutic indices found here might in
part reflect the close species simflarity of the rat and mouse, which enabled the
tumour to grow with facihty in the xenogeneic host and which may also have
enabled us to avoid difficulties that would arise from marked differences in drug
metabolism and disposition. The much greater disparity between mouse and
man may impose nutritional disadvantages on human tumours growing in mice,
and this rnay be reflected in their response to drugs. Differences between the
two species in drug metabolism and disposition, and quantitative differences in844 C. E. SHEARD, J. A. DOUBLE AND M. C. BEMNBAUM
metabolicpathwaysaffectedbyvariousagents htalsobe sufficient to invalidate
comparisons oftherapeutic effectiveness of some drugs.
Second, differences of a more mundane nature may make this method unusable
for many human tumours, for instance, the necessity to use fairly large amounts
of tumour in order to obtain successful transplants (PhiRips and Gazet, 1970).
Further, the generaRy low growth rate of human tumours ht impose an
impracticable delay in dete
i i drug sensitivity, although this would not
be the case where operable tumours were tested weR before the need for chemo-
therapy arose. The extent to which these difficulties might operate in practice
cannot be predicted, and it appears that it would be weR worth attempting to
compare the sensitivity to drugs of a series ofhuman tumours in the patient with
theirsensitivitywhengrown insuitablyimmunosuppressedlaboratory animals.
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